303 results on '"Mohebi, Reza"'
Search Results
2. LIMITED ENGLISH PROFICIENCY, CARDIOVASCULAR RISK FACTORS, CARDIOVASCULAR DISEASE AND IN-HOSPITAL COVID-19 OUTCOME
3. Epidemiological alteration in pathogens found in ground meat in Iran: unexpected predominance of vancomycin-resistant Enterococcus faecalis
4. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
5. Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points
6. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
7. Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin
8. Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction
9. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
10. Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction
11. Abstract 11936: Cardiorenal Prognostic Significance of IGFBP-7 Concentrations in Chronic Heart Failure: Findings From EMPEROR-Pooled
12. Abstract 11776: Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction: Results From the Prospective DEFINE-Type 2 MI Study
13. Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort
14. Race-Free Creatinine-Based Estimation of GFR and Projection of CKD to 2060 in the United States
15. Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
16. Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
17. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
18. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
19. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
20. Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography
21. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
22. Abstract 10409: Performance of the Hart Cve Panel for Prediction of Cardiovascular Events in Patients With Chronic Kidney Disease
23. Abstract 9381: Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
24. Sotagliflozin Efficacy Irrespective of Hemoglobin A1c Level
25. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
26. Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
27. Multiple Biomarkers to Predict Major Adverse Cardiovascular Events in Patients With Coronary Chronic Total Occlusions
28. Oxygen consumption and carbon-dioxide recovery kinetics in the prediction of coronary artery disease severity and outcome
29. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
30. Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
31. Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan
32. CLINICAL PROFILING OF END-STAGE HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE NATIONAL READMISSION DATABASE
33. WHY MEASURE NT-PROBNP SERIALLY IN CHRONIC HEART FAILURE? MECHANISTIC ASSOCIATIONS OF NATRIURETIC PEPTIDE SLOPE FOLLOWING INITIATION OF SACUBITRIL/VALSARTAN
34. DEFINING THE PREVALENCE AND CHARACTERISTICS OF CORONARY ARTERY DISEASE AMONG PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION USING CT-FFR (DEFINE TYPE 2 MI)
35. ATRIAL FIBRILLATION PRIOR TO HEART FAILURE ONSET IS ASSOCIATED WITH ADVERSE OUTCOMES IN PATIENTS REGARDLESS OF LEFT VENTRICULAR EJECTION FRACTION
36. HOW DOES SEX AFFECT ETIOLOGY OF HEART FAILURE? DIFFERENCES BETWEEN WOMEN AND MEN IN THE PRECISION MEDICINE DATABASE FOR AMBULATORY HEART FAILURE PATIENTS (PREFER-HF) STUDY
37. INFLAMMATION ACROSS UNIVERSAL DEFINITION OF HEART FAILURE STAGES: RESULTS OF CASABLANCA STUDY
38. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
39. Traditional and Modern Cell Culture in Virus Diagnosis
40. Cloning, Expression, and Purification of Hyperthermophile α-Amylase from Pyrococcus woesei
41. Obesity Paradox and Risk of Mortality Events in Chronic Kidney Disease Patients: A Decade of Follow-up in Tehran Lipid and Glucose Study
42. Inflammation across universal definition of heart failure stages: the CASABLANCA study
43. Performance of a multi-biomarker panel for prediction of cardiovascular event in patients with chronic kidney disease
44. Wrist circumference as a novel predictor of hypertension and cardiovascular disease: results of a decade follow up in a West Asian cohort
45. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study
46. Biomarker prognostication across Universal Definition of Heart Failure stages
47. Relation of High-Sensitivity Cardiac Troponin I and Obstructive Coronary Artery Disease in Patients Without Acute Myocardial Infarction
48. Reply
49. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?
50. Synthesis and evaluation of monoclonal antibody against Plasmodium falciparum merozoite surface antigen 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.